K. Altundag, "Lapatinib plus capecitabine in metastatic human epidermal growth factor receptor 2-positive breast cancer patients that received prior therapy with trastuzumab and pertuzumab: Better option than T-DM1?," JOURNAL OF BUON , vol.22, no.1, pp.281-282, 2017
Altundag, K. 2017. Lapatinib plus capecitabine in metastatic human epidermal growth factor receptor 2-positive breast cancer patients that received prior therapy with trastuzumab and pertuzumab: Better option than T-DM1?. JOURNAL OF BUON , vol.22, no.1 , 281-282.
Altundag, K., (2017). Lapatinib plus capecitabine in metastatic human epidermal growth factor receptor 2-positive breast cancer patients that received prior therapy with trastuzumab and pertuzumab: Better option than T-DM1?. JOURNAL OF BUON , vol.22, no.1, 281-282.
Altundag, Kadri. "Lapatinib plus capecitabine in metastatic human epidermal growth factor receptor 2-positive breast cancer patients that received prior therapy with trastuzumab and pertuzumab: Better option than T-DM1?," JOURNAL OF BUON , vol.22, no.1, 281-282, 2017
Altundag, Kadri. "Lapatinib plus capecitabine in metastatic human epidermal growth factor receptor 2-positive breast cancer patients that received prior therapy with trastuzumab and pertuzumab: Better option than T-DM1?." JOURNAL OF BUON , vol.22, no.1, pp.281-282, 2017
Altundag, K. (2017) . "Lapatinib plus capecitabine in metastatic human epidermal growth factor receptor 2-positive breast cancer patients that received prior therapy with trastuzumab and pertuzumab: Better option than T-DM1?." JOURNAL OF BUON , vol.22, no.1, pp.281-282.
@article{article, author={Kadri Altundag}, title={Lapatinib plus capecitabine in metastatic human epidermal growth factor receptor 2-positive breast cancer patients that received prior therapy with trastuzumab and pertuzumab: Better option than T-DM1?}, journal={JOURNAL OF BUON}, year=2017, pages={281-282} }